The stock has a 36-month beta value of -1.72. Opinions on the stock are mixed, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for TPST is 17.48M, and at present, short sellers hold a 9.36% of that float. On June 26, 2024, the average trading volume of TPST was 1.34M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
TPST) stock’s latest price update
Tempest Therapeutics Inc (NASDAQ: TPST)’s stock price has soared by 2.91 in relation to previous closing price of 2.06. Nevertheless, the company has seen a loss of -25.61% in its stock price over the last five trading days. benzinga.com reported 2024-06-20 that Shares of Tempest Therapeutics Inc TPST are trading lower on Thursday, with a session volume of 21 million as per data from Benzinga Pro.
TPST’s Market Performance
Tempest Therapeutics Inc (TPST) has seen a -25.61% fall in stock performance for the week, with a -34.67% decline in the past month and a -42.86% plunge in the past quarter. The volatility ratio for the week is 16.02%, and the volatility levels for the past 30 days are at 8.51% for TPST. The simple moving average for the past 20 days is -27.84% for TPST’s stock, with a -37.33% simple moving average for the past 200 days.
Analysts’ Opinion of TPST
Many brokerage firms have already submitted their reports for TPST stocks, with Scotiabank repeating the rating for TPST by listing it as a “Sector Outperform.” The predicted price for TPST in the upcoming period, according to Scotiabank is $13 based on the research report published on March 14, 2024 of the current year 2024.
Jefferies, on the other hand, stated in their research note that they expect to see TPST reach a price target of $15. The rating they have provided for TPST stocks is “Buy” according to the report published on February 08th, 2024.
TPST Trading at -33.85% from the 50-Day Moving Average
After a stumble in the market that brought TPST to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -78.30% of loss for the given period.
Volatility was left at 8.51%, however, over the last 30 days, the volatility rate increased by 16.02%, as shares sank -34.77% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -37.50% lower at present.
During the last 5 trading sessions, TPST fell by -26.75%, which changed the moving average for the period of 200-days by +409.27% in comparison to the 20-day moving average, which settled at $2.88. In addition, Tempest Therapeutics Inc saw -51.82% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for TPST
The total capital return value is set at -0.88. Equity return is now at value -188.37, with -72.84 for asset returns.
Based on Tempest Therapeutics Inc (TPST), the company’s capital structure generated 0.36 points at debt to capital in total, while cash flow to debt ratio is standing at -2.29. The debt to equity ratio resting at 0.56. The interest coverage ratio of the stock is -40.65.
Currently, EBITDA for the company is -28.78 million with net debt to EBITDA at 0.41. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.13.
Conclusion
To sum up, Tempest Therapeutics Inc (TPST) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
